01
The preparation
What exactly are we considering?
Confirm the exact TB4 fragment, formulation and prescribed route with your clinician and pharmacist.
Physician-led care in the UAE
Peptide care · Injection
TB500 (TB4 Fragment) Injection
Research on the fragment includes chemical identification, metabolism and cell experiments. Related unacetylated-fragment studies explore tissue repair, but these sources do not establish a treatment benefit in people.
- Discuss your health goals and suitability with a physician
- Your prescribed preparation is confirmed during care
- Clinical review and follow-up guide the next steps
- Format
- Injection
- Route
- Subcutaneous injection
Suitability reviewed by a UAE-licensed physician
Confirm the dispensing pharmacy and preparation before treatment
Completing an assessment does not guarantee a prescription
Formats reflect the supplied catalog, not a prescription or confirmation of availability. Health topics describe scientific interest, not approved indications. Read the specific studies and preparation limits.
Safety & suitability
Is TB500 (TB4 Fragment) right for you?
These studies do not establish human safety, an effective clinical dose or long-term outcomes. A clinician must assess the exact preparation and your circumstances.
Suitability depends on the specific preparation, intended use and clinical assessment. Product authorization must be verified separately from facility licensing.
The evidence
TB500 (TB4 Fragment):
what has been studied.
The selected research includes chemical identification, laboratory assays and animal studies. Results for the unacetylated fragment are identified separately. These studies do not establish clinical benefit or safety for the listed injection in people.
Researchers measured TB-500 breakdown products. In the cell wound assay, a breakdown product showed activity; TB-500 itself did not significantly improve closure versus control.
Enzyme systems, human serum in the laboratory, rats and cultured fibroblasts · Laboratory exposure and intraperitoneal administration in rats
What remains uncertain
Read the studyA cell scratch assay and rat metabolism measurements do not establish recovery benefits or safety after subcutaneous treatment in people.
Chemical analysis identified the acetylated seven-amino-acid fragment Ac-LKKTETQ in a TB-500 formulation.
A TB-500 formulation and laboratory-synthesized reference material · Laboratory chemical analysis; not a treatment trial
What remains uncertain
Read the studyIdentifying the molecule and developing detection methods does not demonstrate therapeutic benefit, product equivalence or human safety.
The study detected TB-500 and its breakdown products in samples after administration, supporting an analytical detection method.
Horses; urine and plasma samples · Subcutaneous administration in horses
What remains uncertain
Read the studyThis was a detection study in animals, not a test of injury recovery. Findings cannot determine a safe or effective human regimen.
A seven-amino-acid actin-binding motif showed activity in cell movement and vessel-sprouting experiments.
Cultured endothelial cells and chick aortic tissue · Experimental exposure of cells and tissue
What remains uncertain
Read the studyThese are biological mechanisms, not demonstrated healing in patients. The abstract does not establish that the tested material matches acetylated TB500.
The synthetic fragment was associated with improved skin-wound repair in aged mice.
Aged mice in the synthetic-fragment arm · Topical application of the unacetylated LKKTETQ fragment
What remains uncertain
Read the studyThe fragment was unacetylated and applied to skin. This does not establish benefit from acetylated TB500 injections, tendon treatment or use in people.
About this evidence review
TB500 is commonly described as the acetylated fragment Ac-LKKTETQ. Studies of the unacetylated sequence or full-length parent protein cannot establish the effects of this subcutaneous preparation. The selected sources are analytical, cell or animal studies, not human treatment trials.
Read the FDA assessment of fragment identity and evidence limitations
Reviewed November 6, 2026. Selected publications, not a systematic review. Findings do not establish product authorization.
Our review approachFor your consultation
Know what to ask.
Three questions to help you discuss TB500 (TB4 Fragment) Injection. Your clinician decides which preparation, checks and follow-up are relevant.
02
Your assessment
What needs checking first?
Which checks are appropriate before treatment?
03
Your follow-up
How will we review the plan?
Which symptoms should prompt contacting the care team?
These questions are not a dosing schedule or a required test panel. Your clinician individualizes the plan.
A considered approach
to peptide care.
A peptide name is only the beginning. The preparation, clinical need and available evidence all matter to the decision.
Dr. Sami Mohammed Yesuf, MD
Medical Director & Physician, DarDoc
Dr. Marwa Abuaita, MD
Physician, DarDoc
- 01
Start with the clinical question
Discuss the symptoms or diagnosis behind your interest in a peptide, alongside current medicines and previous treatment.
- 02
Review the exact preparation
Consider the evidence for its route and intended use, its regulatory status, and established treatment alternatives.
- 03
Make an informed decision
Discuss potential benefits, uncertainties and risks. A prescription is considered only when clinically appropriate and permitted.
- 04
Agree how to review progress
If treatment is prescribed, agree on monitoring, side effects to report and when to reassess the plan.
SCOPE credentials shown relate to obesity medicine, not peptide-specific certification. The treating physician is confirmed at booking.
A few things to know
Your questions,
answered.
How is TB500 (TB4 Fragment) Injection considered in a consultation?
Your physician reviews your symptoms, history, current medicines and goals. The discussion should include the specific evidence, risks, alternatives and a follow-up plan before any treatment decision.
What should I know about the safety of TB500 (TB4 Fragment) Injection?
These studies do not establish human safety, an effective clinical dose or long-term outcomes. A clinician must assess the exact preparation and your circumstances.
Can I order without a consultation?
Prescription treatment is considered only after clinical assessment. Browsing a format does not select a dose, determine eligibility or guarantee a prescription.
Continue exploring
More in this area.
Explore other products discussed in these health topics, with the evidence for each.
DarDoc peptidesPen
Recovery · Skin & hair · Digestive health
BPC-157 Pen
2 mg/ml · 3 ml
Early human reports describe improvements in specific pain and bladder conditions. The preparation and treatment site matter.
DarDoc peptidesCapsules
Recovery · Skin & hair · Digestive health
BPC-157 Capsules
500 mcg Capsule · 30 Capsules
Early human reports describe improvements in specific pain and bladder conditions. The preparation and treatment site matter.
Bring your questions
Make your next step
a conversation.
Want to understand where TB500 (TB4 Fragment) Injection fits? Discuss the evidence, your health history and the options with DarDoc.